Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.94
BMRN's Cash to Debt is ranked lower than
79% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. BMRN: 0.94 )
Ranked among companies with meaningful Cash to Debt only.
BMRN' s Cash to Debt Range Over the Past 10 Years
Min: 0.12  Med: 1.15 Max: No Debt
Current: 0.94
Equity to Asset 0.63
BMRN's Equity to Asset is ranked lower than
55% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BMRN: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
BMRN' s Equity to Asset Range Over the Past 10 Years
Min: -0.66  Med: 0.57 Max: 0.97
Current: 0.63
-0.66
0.97
F-Score: 2
Z-Score: 5.22
M-Score: -2.19
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -30.27
BMRN's Operating margin (%) is ranked higher than
58% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. BMRN: -30.27 )
Ranked among companies with meaningful Operating margin (%) only.
BMRN' s Operating margin (%) Range Over the Past 10 Years
Min: -250.16  Med: -17.19 Max: 13.41
Current: -30.27
-250.16
13.41
Net-margin (%) -34.68
BMRN's Net-margin (%) is ranked higher than
57% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. BMRN: -34.68 )
Ranked among companies with meaningful Net-margin (%) only.
BMRN' s Net-margin (%) Range Over the Past 10 Years
Min: -289.34  Med: -15.42 Max: 54.7
Current: -34.68
-289.34
54.7
ROE (%) -15.34
BMRN's ROE (%) is ranked higher than
62% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. BMRN: -15.34 )
Ranked among companies with meaningful ROE (%) only.
BMRN' s ROE (%) Range Over the Past 10 Years
Min: -141.46  Med: -9.34 Max: 39.6
Current: -15.34
-141.46
39.6
ROA (%) -9.78
BMRN's ROA (%) is ranked higher than
66% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. BMRN: -9.78 )
Ranked among companies with meaningful ROA (%) only.
BMRN' s ROA (%) Range Over the Past 10 Years
Min: -34.68  Med: -4.93 Max: 18.88
Current: -9.78
-34.68
18.88
ROC (Joel Greenblatt) (%) -35.58
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. BMRN: -35.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BMRN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -144.43  Med: -11.37 Max: 31.1
Current: -35.58
-144.43
31.1
Revenue Growth (3Y)(%) 9.20
BMRN's Revenue Growth (3Y)(%) is ranked higher than
63% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. BMRN: 9.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BMRN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.1  Med: 12.75 Max: 97.7
Current: 9.2
-11.1
97.7
EPS Growth (3Y)(%) 24.00
BMRN's EPS Growth (3Y)(%) is ranked higher than
80% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BMRN: 24.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BMRN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.5  Med: 12.75 Max: 475.1
Current: 24
-75.5
475.1
» BMRN's 10-Y Financials

Financials (Next Earnings Date: 2016-02-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

BMRN Guru Trades in Q4 2014

RS Investment Management 94,400 sh (New)
Louis Moore Bacon 56,100 sh (New)
Frank Sands 12,183,113 sh (+0.70%)
Manning & Napier Advisors, Inc 288,180 sh (unchged)
John Griffin 2,230,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 8,016,518 sh (-0.34%)
Columbia Wanger 416,200 sh (-51.25%)
Steven Cohen 74,600 sh (-88.96%)
» More
Q1 2015

BMRN Guru Trades in Q1 2015

Signature Select Canadian Fund 18,300 sh (New)
Joel Greenblatt 4,195 sh (New)
Frank Sands 12,335,452 sh (+1.25%)
PRIMECAP Management 8,025,008 sh (+0.11%)
John Griffin 2,230,000 sh (unchged)
Steven Cohen Sold Out
Columbia Wanger Sold Out
Manning & Napier Advisors, Inc Sold Out
Louis Moore Bacon 27,500 sh (-50.98%)
RS Investment Management 33,900 sh (-64.09%)
» More
Q2 2015

BMRN Guru Trades in Q2 2015

Paul Tudor Jones 2,062 sh (New)
Kyle Bass 9,886 sh (New)
Jim Simons 123,671 sh (New)
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 7,992,749 sh (-0.40%)
RS Investment Management 32,570 sh (-3.92%)
John Griffin 2,120,000 sh (-4.93%)
Frank Sands 11,627,607 sh (-5.74%)
» More
Q3 2015

BMRN Guru Trades in Q3 2015

Kyle Bass 129,501 sh (+1209.94%)
Paul Tudor Jones 6,208 sh (+201.07%)
Jim Simons 262,571 sh (+112.31%)
RS Investment Management 55,060 sh (+69.05%)
Frank Sands 11,395,866 sh (-1.99%)
Signature Select Canadian Fund 17,500 sh (-4.37%)
PRIMECAP Management 7,365,039 sh (-7.85%)
John Griffin 1,540,000 sh (-27.36%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.54
BMRN's P/B is ranked lower than
65% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. BMRN: 4.54 )
Ranked among companies with meaningful P/B only.
BMRN' s P/B Range Over the Past 10 Years
Min: 3.68  Med: 6.88 Max: 27.54
Current: 4.54
3.68
27.54
P/S 11.34
BMRN's P/S is ranked lower than
55% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. BMRN: 11.34 )
Ranked among companies with meaningful P/S only.
BMRN' s P/S Range Over the Past 10 Years
Min: 3.37  Med: 15.42 Max: 34
Current: 11.34
3.37
34
Current Ratio 3.01
BMRN's Current Ratio is ranked lower than
62% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. BMRN: 3.01 )
Ranked among companies with meaningful Current Ratio only.
BMRN' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 6.47 Max: 18.94
Current: 3.01
0.9
18.94
Quick Ratio 2.34
BMRN's Quick Ratio is ranked lower than
66% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BMRN: 2.34 )
Ranked among companies with meaningful Quick Ratio only.
BMRN' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 5.35 Max: 18.77
Current: 2.34
0.82
18.77
Days Inventory 529.70
BMRN's Days Inventory is ranked lower than
97% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. BMRN: 529.70 )
Ranked among companies with meaningful Days Inventory only.
BMRN' s Days Inventory Range Over the Past 10 Years
Min: 367.05  Med: 517.63 Max: 917.29
Current: 529.7
367.05
917.29
Days Sales Outstanding 60.78
BMRN's Days Sales Outstanding is ranked higher than
54% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. BMRN: 60.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.96  Med: 78.96 Max: 86.7
Current: 60.78
50.96
86.7
Days Payable 61.45
BMRN's Days Payable is ranked higher than
51% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. BMRN: 61.45 )
Ranked among companies with meaningful Days Payable only.
BMRN' s Days Payable Range Over the Past 10 Years
Min: 23.24  Med: 67.20 Max: 140.65
Current: 61.45
23.24
140.65

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.93
BMRN's Price/Tangible Book is ranked lower than
77% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. BMRN: 8.93 )
Ranked among companies with meaningful Price/Tangible Book only.
BMRN' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.13  Med: 7.37 Max: 111.83
Current: 8.93
2.13
111.83
Price/Projected FCF 26.42
BMRN's Price/Projected FCF is ranked lower than
91% of the 150 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. BMRN: 26.42 )
Ranked among companies with meaningful Price/Projected FCF only.
BMRN' s Price/Projected FCF Range Over the Past 10 Years
Min: 19.71  Med: 31.10 Max: 234.29
Current: 26.42
19.71
234.29
Price/Median PS Value 0.74
BMRN's Price/Median PS Value is ranked higher than
61% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. BMRN: 0.74 )
Ranked among companies with meaningful Price/Median PS Value only.
BMRN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.19 Max: 10
Current: 0.74
0.26
10
Earnings Yield (Greenblatt) (%) -2.55
BMRN's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. BMRN: -2.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BMRN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.55  Med: 1.20 Max: 4.1
Current: -2.55
-2.55
4.1

More Statistics

Revenue(Mil) $895
EPS $ -2.01
Beta1.80
Short Percentage of Float4.76%
52-Week Range $64.00 - 151.75
Shares Outstanding(Mil)161.25

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 889 1,136 1,422 1,707
EPS($) -0.67 -1.75 -1.16 0.36
EPS without NRI($) -0.67 -1.75 -1.16 0.36

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 

More From Other Websites
BioMarin Pharmaceutical's Illness Could Be Cured Feb 08 2016
It’s Time to Buy This Biotech Gem Feb 04 2016
Headline Risk Is Poison for Pharma and Biotech Feb 03 2016
Pre-Market Pulse on Biotechnology Stocks -- ZIOPHARM Oncology, BioMarin Pharma, PTC Therapeutics,... Feb 01 2016
BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on... Jan 28 2016
BioMarin to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on... Jan 28 2016
Changes in BioMarin’s Valuation Multiples Jan 26 2016
Duchenne drug by Cambridge's Catabasis looks safe in early trial Jan 25 2016
Snowstorm Dashes Hopes for Sarepta Drug's Dystrophy Patients Jan 22 2016
The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug Jan 21 2016
Muscular Dystrophy Drugs Face New FDA Questions Jan 20 2016
Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie Jan 20 2016
Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus Jan 20 2016
10 Biotech Buys from Credit Suisse Jan 20 2016
Coverage initiated on Biomarin Pharm by Credit Suisse Jan 20 2016
What Are the Potential Drivers of BioMarin? Jan 19 2016
What Are Analysts’ Expectations for BioMarin? Jan 19 2016
​Science, and not patients, will turn the tide for Sarepta's Duchenne drug Jan 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK